Gennex Lab.

{
  "main_header": {
    "sid": 930938,
    "name": "Gennex Lab.",
    "stock_name": "Gennex Lab.",
    "full_name": "Gennex Laboratories Ltd",
    "name_url": "stocks-analysis/gennex-lab",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "10.68",
    "chg": -0.03,
    "chgp": "-0.28%",
    "dir": -1,
    "prev_price": "10.71",
    "mcapval": "265.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531739,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE509C01026",
    "curr_date": "Jun 17, 12:40 PM",
    "curr_time": "12:42 PM",
    "last_traded_at": "Jun 17, 12:40 PM IST",
    "bse_nse_vol": "1.31 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 17, 2026",
    "traded_date_str": "2026 06 17",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/gennex-lab-930938-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Gennex Laboratories Ltd Upgraded to Hold on Technical and Financial Improvements",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gennex-laboratories-ltd-upgraded-to-hold-on-technical-and-financial-improvements-4058400",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GennexLaborator_mojoScore_4058400.png",
        "date": "2026-06-17 08:29:14",
        "description": "Gennex Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and financial performance. The upgrade, effective from 16 June 2026, is driven by a combination of enhanced technical trends, solid quarterly financial results, attractive valuation metrics, and a stable quality profile, signalling a cautious but optimistic outlook for this micro-cap pharmaceutical player."
      },
      {
        "title": "Gennex Laboratories Declines 9.77% Amid Strong Quarterly Turnaround and Valuation Reset",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gennex-laboratories-declines-977-amid-strong-quarterly-turnaround-and-valuation-reset-4052107",
        "imagepath": "",
        "date": "2026-06-13 16:26:02",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>1 June:</strong> Strong quarterly turnaround reported with profit before tax surging 1251.85%</p>\n                    <p><strong>2 June:</strong> Valuation metrics improve, signalling renewed price attractiveness</p>\n                    <p><strong>5 June:</strong> Stock closes the week at ₹10.62, down 9.77%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">₹11.77</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">₹10.62</div><div class=\"stat-change negative\">-9.77%</div></div>\n               ..."
      },
      {
        "title": "Gennex Laboratories Downgraded to Sell Amid Technical Weakness and Market Underperformance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gennex-laboratories-downgraded-to-sell-amid-technical-weakness-and-market-underperformance-4048460",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GennexLaborator_mojoScore_4048460.png",
        "date": "2026-06-12 08:14:53",
        "description": "Gennex Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 11 June 2026. This revision reflects a combination of deteriorating technical indicators, valuation concerns, and underwhelming recent market performance despite some positive financial trends."
      },
      {
        "title": "Gennex Laboratories Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/gennex-laboratories-ltd-is-rated-hold-4046425",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GennexLaborator_mojoScore_4046425.png",
        "date": "2026-06-11 10:10:40",
        "description": "Gennex Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Are Gennex Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-gennex-laboratories-ltd-latest-results-good-or-bad-4032452",
        "imagepath": "",
        "date": "2026-06-02 19:35:43",
        "description": "Gennex Laboratories Ltd's latest financial results for the quarter ended March 2026 present a complex picture. The company achieved net sales of ₹60.96 crores, reflecting a substantial year-on-year growth of 51.15%, which marks the highest quarterly revenue in its recent history. This growth indicates robust demand for Gennex's products, particularly in the active pharmaceutical ingredients (API) and intermediates segment.\n\nHowever, this impressive top-line growth was not mirrored in profitability metrics. The operating margin, excluding other income, fell sharply to 9.66% from 23.61% in the same quarter last year, indicating significant margin compression. This decline raises concerns about the company's cost management and pricing strategies, suggesting that the growth may have come at the expense of profitability. The net profit for the quarter was reported at ₹3.74 crores, which, while showing a year-on..."
      },
      {
        "title": "Gennex Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gennex-laboratories-ltd-valuation-shifts-signal-renewed-price-attractiveness-4029412",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GennexLaborator_valuationdot_4029412.png",
        "date": "2026-06-02 08:04:15",
        "description": "Gennex Laboratories Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive rating, driven by a notable decline in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change comes against a backdrop of mixed sector performance and a challenging market environment, prompting investors to reassess the stock’s price attractiveness relative to its peers and historical benchmarks."
      },
      {
        "title": "Gennex Laboratories Q4 FY26: Profit Surge Masks Margin Compression Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/gennex-laboratories-q4-fy26-profit-surge-masks-margin-compression-concerns-4028764",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GennexLaborator_quaterlyResult_4028764.png",
        "date": "2026-06-01 15:16:03",
        "description": "Gennex Laboratories Ltd., a micro-cap pharmaceutical manufacturer specialising in active pharmaceutical ingredients and intermediates, reported consolidated net profit of ₹3.74 crores for Q4 FY26, marking a robust 61.21% year-on-year growth but a concerning 28.63% sequential decline. The Telangana-based company, with a market capitalisation of ₹285.00 crores, saw its stock retreat 4.42% to ₹11.25 following the results announcement, reflecting investor concerns over deteriorating operating margins despite impressive top-line expansion."
      },
      {
        "title": "Gennex Laboratories Ltd Reports Strong Quarterly Turnaround Amid Mixed Long-Term Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/gennex-laboratories-ltd-reports-strong-quarterly-turnaround-amid-mixed-long-term-returns-4026587",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GennexLaborator_fintrenddot_4026587.png",
        "date": "2026-06-01 12:01:16",
        "description": "Gennex Laboratories Ltd has demonstrated a notable turnaround in its financial performance for the quarter ended March 2026, with significant growth in profitability and revenue, despite a challenging market environment and a recent downgrade in its Mojo Grade to Sell."
      },
      {
        "title": "Are Gennex Laboratories Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-gennex-laboratories-ltd-latest-results-good-or-bad-4023909",
        "imagepath": "",
        "date": "2026-05-30 19:51:14",
        "description": "Gennex Laboratories Ltd's latest financial results present a mixed picture, highlighting both robust revenue growth and significant operational challenges. For the fiscal year 2025, the company reported a notable net sales increase of 59.30% year-on-year, reaching ₹137.00 crores, up from ₹86.00 crores in the previous year. This growth is supported by a strong five-year compound annual growth rate (CAGR) of 22.71%, indicating a consistent upward trend in sales.\n\nHowever, the operational metrics reveal concerning trends. The net profit for FY25 rose to ₹18.00 crores, reflecting a 38.46% increase year-on-year, but this growth lagged behind the sales expansion. The profit after tax margin contracted to 13.10% from 15.10% in FY24, suggesting deteriorating operational efficiency. Furthermore, the operating margin (excluding other income) saw a significant decline, dropping to 11.70% from 19.80%, raising questions..."
      }
    ],
    "total": 178,
    "sid": "930938",
    "stock_news_url": "https://www.marketsmojo.com/news/gennex-laboratories-930938"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
      "datetime": "10-Jun-2026",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on June 10 2026 for Premier Fiscal Services Pvt Ltd",
      "source": "BSE"
    },
    {
      "caption": "Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.",
      "datetime": "10-Jun-2026",
      "details": "The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011 on June 10 2026 for Premier Fiscal Services Pvt Ltd",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.",
      "datetime": "10-Jun-2026",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on June 10 2026 for Premier Fiscal Services Pvt Ltd",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Gennex Laboratories Ltd has announced <strong>1:10</strong> stock split, ex-date: 14 Dec 09",
          "dt": "2009-12-14",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Gennex Laboratories Ltd has announced <strong>1:2</strong> rights issue, ex-date: 21 Jul 22",
          "dt": "2022-07-21",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Gennex Laboratories Ltd Upgraded to Hold on Technical and Financial Improvements

2026-06-17 08:29:14

Gennex Laboratories Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and financial performance. The upgrade, effective from 16 June 2026, is driven by a combination of enhanced technical trends, solid quarterly financial results, attractive valuation metrics, and a stable quality profile, signalling a cautious but optimistic outlook for this micro-cap pharmaceutical player.

Read full news article

Gennex Laboratories Declines 9.77% Amid Strong Quarterly Turnaround and Valuation Reset

2026-06-13 16:26:02

Key Events This Week

1 June: Strong quarterly turnaround reported with profit before tax surging 1251.85%

2 June: Valuation metrics improve, signalling renewed price attractiveness

5 June: Stock closes the week at ₹10.62, down 9.77%

Week Open

₹11.77

Week Close

₹10.62

-9.77%

...

Read full news article

Gennex Laboratories Downgraded to Sell Amid Technical Weakness and Market Underperformance

2026-06-12 08:14:53

Gennex Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 11 June 2026. This revision reflects a combination of deteriorating technical indicators, valuation concerns, and underwhelming recent market performance despite some positive financial trends.

Read full news article

Gennex Laboratories Ltd is Rated Hold

2026-06-11 10:10:40

Gennex Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Are Gennex Laboratories Ltd latest results good or bad?

2026-06-02 19:35:43

Gennex Laboratories Ltd's latest financial results for the quarter ended March 2026 present a complex picture. The company achieved net sales of ₹60.96 crores, reflecting a substantial year-on-year growth of 51.15%, which marks the highest quarterly revenue in its recent history. This growth indicates robust demand for Gennex's products, particularly in the active pharmaceutical ingredients (API) and intermediates segment. However, this impressive top-line growth was not mirrored in profitability metrics. The operating margin, excluding other income, fell sharply to 9.66% from 23.61% in the same quarter last year, indicating significant margin compression. This decline raises concerns about the company's cost management and pricing strategies, suggesting that the growth may have come at the expense of profitability. The net profit for the quarter was reported at ₹3.74 crores, which, while showing a year-on...

Read full news article

Gennex Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness

2026-06-02 08:04:15

Gennex Laboratories Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive rating, driven by a notable decline in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change comes against a backdrop of mixed sector performance and a challenging market environment, prompting investors to reassess the stock’s price attractiveness relative to its peers and historical benchmarks.

Read full news article

Gennex Laboratories Q4 FY26: Profit Surge Masks Margin Compression Concerns

2026-06-01 15:16:03

Gennex Laboratories Ltd., a micro-cap pharmaceutical manufacturer specialising in active pharmaceutical ingredients and intermediates, reported consolidated net profit of ₹3.74 crores for Q4 FY26, marking a robust 61.21% year-on-year growth but a concerning 28.63% sequential decline. The Telangana-based company, with a market capitalisation of ₹285.00 crores, saw its stock retreat 4.42% to ₹11.25 following the results announcement, reflecting investor concerns over deteriorating operating margins despite impressive top-line expansion.

Read full news article

Gennex Laboratories Ltd Reports Strong Quarterly Turnaround Amid Mixed Long-Term Returns

2026-06-01 12:01:16

Gennex Laboratories Ltd has demonstrated a notable turnaround in its financial performance for the quarter ended March 2026, with significant growth in profitability and revenue, despite a challenging market environment and a recent downgrade in its Mojo Grade to Sell.

Read full news article

Are Gennex Laboratories Ltd latest results good or bad?

2026-05-30 19:51:14

Gennex Laboratories Ltd's latest financial results present a mixed picture, highlighting both robust revenue growth and significant operational challenges. For the fiscal year 2025, the company reported a notable net sales increase of 59.30% year-on-year, reaching ₹137.00 crores, up from ₹86.00 crores in the previous year. This growth is supported by a strong five-year compound annual growth rate (CAGR) of 22.71%, indicating a consistent upward trend in sales. However, the operational metrics reveal concerning trends. The net profit for FY25 rose to ₹18.00 crores, reflecting a 38.46% increase year-on-year, but this growth lagged behind the sales expansion. The profit after tax margin contracted to 13.10% from 15.10% in FY24, suggesting deteriorating operational efficiency. Furthermore, the operating margin (excluding other income) saw a significant decline, dropping to 11.70% from 19.80%, raising questions...

Read full news article

View All News